NASDAQ:SYRS

Syros Pharmaceuticals Stock Forecast, Price & News

$14.10

+0.27 (+1.95 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$13.44

Now: $14.10▼

$14.99

50-Day Range

$7.64

MA: $10.85▼

$14.66

52-Week Range

$4.26

Now: $14.10▼

$15.65

Volume803,143 shs

Average Volume716,887 shs

Market Capitalization$792.42 million

P/E RatioN/A

Dividend YieldN/A

Beta2.01

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.15 out of 5 stars

2.5 Analyst's Opinion

Consensus Rating
Syros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.57, Syros Pharmaceuticals has a forecasted upside of 24.6% from its current price of $14.10.
Amount of Analyst Coverage
Syros Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Syros Pharmaceuticals has received 343 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Syros Pharmaceuticals has received 314 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Syros Pharmaceuticals has received 52.21% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote “Outperform” if you believe SYRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Syros Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Syros Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syros Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,639.00 in company stock.
Percentage Held by Insiders
Only 14.80% of the stock of Syros Pharmaceuticals is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($1.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Syros Pharmaceuticals is -8.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syros Pharmaceuticals is -8.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Syros Pharmaceuticals has a P/B Ratio of 7.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SYRS

Previous Symbol

CUSIPN/A

CIK1556263

Webwww.syros.com

Phone617-744-1340

Employees83

Debt

Debt-to-Equity Ratio0.44

Current Ratio3.51

Quick Ratio3.51

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.98 million

Price / Sales400.21

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.87 per share

Price / Book7.54

Profitability

EPS (Most Recent Fiscal Year)($1.88)

Net Income$-75,440,000.00

Net Margins-743.58%

Return on Equity-111.54%

Return on Assets-49.71%

Miscellaneous

Outstanding Shares56,200,000

Market Cap$792.42 million

Next Earnings Date3/4/2021 (Estimated)

OptionableOptionable

$14.10

+0.27 (+1.95 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

How has Syros Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SYRS stock has increased by 173.8% and is now trading at $14.10.
View which stocks have been most impacted by COVID-19.

Is Syros Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Syros Pharmaceuticals?

Wall Street analysts have given Syros Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Syros Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Syros Pharmaceuticals.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.43) EPS for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.05. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $2.83 million. Syros Pharmaceuticals had a negative return on equity of 111.54% and a negative net margin of 743.58%.
View Syros Pharmaceuticals' earnings history.

What price target have analysts set for SYRS?

8 brokerages have issued 12-month price objectives for Syros Pharmaceuticals' shares. Their forecasts range from $13.00 to $20.00. On average, they expect Syros Pharmaceuticals' share price to reach $17.57 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Syros Pharmaceuticals' key competitors?

Some companies that are related to Syros Pharmaceuticals include Karuna Therapeutics (KRTX), Intra-Cellular Therapies (ITCI), Cryoport (CYRX), Zymeworks (ZYME), Amarin (AMRN), Seres Therapeutics (MCRB), Arcus Biosciences (RCUS), Praxis Precision Medicines (PRAX), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY), PMV Pharmaceuticals (PMVP), Zentalis Pharmaceuticals (ZNTL), Viela Bio (VIE), Shattuck Labs (STTK) and Stoke Therapeutics (STOK).
View all of SYRS's competitors.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:

Dr. Nancy A. Simonian, Pres, CEO & Director (Age 59, Pay $897.05k)
Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 66, Pay $165k)
Dr. Eric R. Olson, Chief Scientific Officer (Age 62, Pay $638.63k)
Dr. David A. Roth, Chief Medical Officer (Age 57, Pay $641.48k)
Dr. Nathanael S. Gray Ph.D., Scientific Founder & Member of Scientific Advisory Board
Mr. Joseph J. Ferra Jr., Chief Financial Officer (Age 44)
Mr. Gerald E. Quirk, Chief Legal & Admin. Officer and Sec. (Age 52)
Ms. Naomi Aoki, VP of Corp. Communications & Investor Relations
Dr. Christian C. Fritz, Head of Biology
Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 58)

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $14.10.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $792.42 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 83 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here